Studies on mouse models of T2DM have indicated that the hyperglycemia environment of T2DM prompted the increased production of reactive metabolites, such as methylglyoxal (MGO), which act as TRPA-1 agonists. Here, TRPA1 is linked to Hyperglycemia.